[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"postpartum-hypertension-ppht\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:postpartum-hypertension-ppht":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100586470","phase-4-peace-trial-postpartum-evaluation-of-antihypertensive-cessation-and-efficacy-100586470",false,"NCT06915792","PEACE Trial: Postpartum Evaluation of Antihypertensive Cessation and Efficacy","Postpartum Evaluation of Antihypertensive Cessation and Efficacy (PEACE): A Randomized Controlled Trial Comparing Oral Labetalol and Oral Extended-Release Nifedipine for Managing Postpartum Hypertension","PEACE","Inclusion criteria:\n\nAge ≥18 years Delivery at study institution at ≥28 weeks gestation Postpartum SBP \\> 150 and\u002For DBP \\> 100 OR 2 or more SBP \\> 140 and\u002For DBP \\> 90 within a 24-hour period Require initiation of an oral antihypertensive medication during postpartum hospital stay or within 7 days of discharge Treating obstetric team amenable to starting either study medication\n\nExclusion criteria:\n\nTreated with oral antihypertensive medications prior to delivery Known allergies or contraindications to nifedipine or labetalol History of moderate persistent to severe asthma, chronic obstructive pulmonary disease, heart failure, or greater than first-degree atrioventricular heart block Unable to provide written informed consent in English","FEMALE","18 Years","64 Years",{"count":21,"type":22},110,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","This randomized controlled trial compares two common medications, labetalol and extended-release nifedipine, to determine which is more effective at managing postpartum high blood pressure. We hypothesize that extended-release nifedipine will better control blood pressure and reduce the need for continued medication beyond six weeks postpartum. The study will enroll 110 postpartum participants, randomly assigning them to one of the two medications, with remote blood pressure monitoring to evaluate treatment effectiveness and inform postpartum hypertension management.",[28],"Postpartum Hypertension (PPHT)",[30],"postpartum hypertension, blood pressure control, labetalol, nifedipine, antihypertensive therapy, pregnancy hypertension, maternal health, randomized controlled","RECRUITING","2026-06-03",{"date":34,"type":35},"2026-06-05","ACTUAL",{"date":37,"type":35},"2025-06-01",{"date":39,"type":22},"2027-10-31",{"name":41,"class":42},"University of California, Los Angeles","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":43},"100415517","swiss-postpartum-hypertension-cohort-100415517","NCT04690660","Swiss Postpartum Hypertension Cohort","Swiss Postpartum Hypertension Cohort (Swiss-PPHT)","Inclusion Criteria:\n\n* all women with hypertensive disorders of pregnancy\n* postpartum hypertension (blood pressure measurements of systolic ≥140 and\u002For diastolic ≥ 90mmHg or antihypertensive therapy within the first 14 days after delivery)\n* women with preexisting hypertension or\n* women on antihypertensive medication\n\nExclusion Criteria:\n\n* delivery \\> 14 days\n* lack of consent to participate in the study, language barriers or lack of general understanding",{"count":52,"type":22},480,"OBSERVATIONAL","This open label, prospective observational, single-center registry is to study short-, intermediate-and long-term course of postpartum hypertension and predictors\u002Frisk factors associated with long term cardiovascular and renal risk.\n\nCurrent disease management strategies will be evaluated.",[28],[57,58,59,60,61,62],"Pregnancy Induced Hypertension (PIH)","Home Blood Pressure Monitoring (HBPM)","Office Blood Pressure Monitoring (OBPM)","Automated Office Blood Pressure Measurement (AOBPM)","Gestational Hypertension","HekaHealth Self-Measured Blood Pressure (SMBP) App","2025-05-21",{"date":65,"type":35},"2025-05-28",{"date":67,"type":35},"2020-06-04",{"date":69,"type":22},"2030-05",{"name":71,"class":42},"University Hospital, Basel, Switzerland"]